Citigroup initiated coverage on Telix Pharmaceuticals with a new price target
$TLX
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $22.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2025 | $22.00 | Buy | Citigroup |
| 8/28/2025 | Overweight → Neutral | Analyst | |
| 7/3/2025 | $23.00 | Buy | H.C. Wainwright |
| 6/5/2025 | $22.00 | Outperform | Wedbush |
| 11/15/2024 | $21.00 | Buy | UBS |
4 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)
3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)
3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)
Citigroup initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $22.00
Analyst downgraded Telix Pharmaceuticals from Overweight to Neutral
H.C. Wainwright initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $23.00
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He current
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients. Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed. Key findings includ
6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)
20-F/A - Telix Pharmaceuticals Ltd (0002007191) (Filer)
6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed. Key findings includ
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adjusted operating cash flow Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4.US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance.Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategi
MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT (Thursday, 19 February 2026 EST). An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday, 20 February 2026 (5:30 p.m. EST, Thursday, 19 February 2026). Participants can register at the following link: https://edge.media-server.com/mmc/p/famdpwzh About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceu
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He current
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada's particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotr
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC